204 related articles for article (PubMed ID: 37515199)
21. The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study.
So M; Steiger DJ; Takahashi M; Egorova NN; Kuno T
J Thromb Thrombolysis; 2021 Nov; 52(4):1061-1067. PubMed ID: 33966157
[TBL] [Abstract][Full Text] [Related]
22. Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-positive patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system.
Erben Y; Franco-Mesa C; Gloviczki P; Stone W; Quinones-Hinojoas A; Meltzer AJ; Lin M; Greenway MRF; Hamid O; Devcic Z; Toskich B; Ritchie C; Lamb CJ; De Martino RR; Siegel J; Farres H; Hakaim AG; Sanghavi DK; Li Y; Rivera C; Moreno-Franco P; O'Keefe NL; Gopal N; Marquez CP; Huang JF; Kalra M; Shields R; Prudencio M; Gendron T; McBane R; Park M; Hoyne JB; Petrucelli L; O'Horo JC; Meschia JF
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1361-1370.e1. PubMed ID: 33836287
[TBL] [Abstract][Full Text] [Related]
23. Successful use of tPA for thrombolysis in COVID related ARDS: a case series.
Goyal A; Saigal S; Niwariya Y; Sharma J; Singh P
J Thromb Thrombolysis; 2021 Feb; 51(2):293-296. PubMed ID: 32617806
[TBL] [Abstract][Full Text] [Related]
24. Systemic thrombolytics as rescue therapy for COVID-19 patients with acute respiratory distress syndrome: A retrospective observational study.
Ashwathappa PG; Jacob I; Rangappa P; Rao K
Int J Crit Illn Inj Sci; 2022; 12(4):197-203. PubMed ID: 36779209
[TBL] [Abstract][Full Text] [Related]
25. Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism.
Islam MS
Adv Exp Med Biol; 2017; 906():67-74. PubMed ID: 27628004
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Thrombolysis in COVID-19 Related ARDS.
Goyal A; Niwariya Y; Pawar N; Khurana A; Chaudhary P
Recent Adv Antiinfect Drug Discov; 2023; 18(3):197-204. PubMed ID: 36237163
[TBL] [Abstract][Full Text] [Related]
27. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.
Goldhaber SZ; Haire WD; Feldstein ML; Miller M; Toltzis R; Smith JL; Taveira da Silva AM; Come PC; Lee RT; Parker JA
Lancet; 1993 Feb; 341(8844):507-11. PubMed ID: 8094768
[TBL] [Abstract][Full Text] [Related]
28. Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase.
Lillyblad MP; Qadri GA; Weise BE; Smith CS; St Hill C; Tierney DM; Melamed RR
J Thromb Thrombolysis; 2022 Nov; 54(4):605-615. PubMed ID: 35320471
[TBL] [Abstract][Full Text] [Related]
29. Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis.
Bais B; Sozio E; De Silvestri D; Volpetti S; Zannier ME; Filì C; Bassi F; Alcaro L; Cotrufo M; Pagotto A; Giacinta A; Patruno V; Da Porto A; Sbrojavacca R; Curcio F; Tascini C; Sechi LA; Colussi G
Thromb J; 2022 Jun; 20(1):34. PubMed ID: 35725464
[TBL] [Abstract][Full Text] [Related]
30. Systemic thrombolysis for acute pulmonary embolism.
Bartel B
Hosp Pract (1995); 2015; 43(1):22-7. PubMed ID: 25559613
[TBL] [Abstract][Full Text] [Related]
31. Thrombolytic Therapy for Pulmonary Embolism in COVID 19 ARDS: A Case Series.
Yelle S
J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062801
[TBL] [Abstract][Full Text] [Related]
32. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism.
Graif A; Kimbiris G; Grilli CJ; Agriantonis DJ; Putnam SG; Leung DA
J Vasc Interv Radiol; 2020 Apr; 31(4):537-543. PubMed ID: 31959518
[TBL] [Abstract][Full Text] [Related]
33. Incidence & outcomes of clinically significant bleeding events in critically ill COVID-19 patients receiving Therapeutic dose AntiCoagulanTs: A retrospective cohort study (INTerACT study).
Singh A; Dhir A; Kajal K; Naik NB; Lazar MS; Puri GD; Soni SL; Neupane A; Ganesh V; Kaloria N; Saini K; Hazarika A; Mahajan V; Singla K; Bhalla A
Indian J Med Res; 2022; 155(5&6):526-537. PubMed ID: 36124497
[TBL] [Abstract][Full Text] [Related]
34. Thrombolytic treatment (alteplase; rt-Pa) in acute massive pulmonary embolism and cardiopulmonary arrest.
Dirican A; Ozkaya S; Atas AE; Ulu EK; Kitapci I; Ece F
Drug Des Devel Ther; 2014; 8():759-63. PubMed ID: 24959070
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary embolism in patients with severe COVID-19 treated with systemic low-dose thrombolytic therapy: A case series.
Aribawa IGNM; Ryalino C; Pradhana AP; Dewi PU; Sinardja CWD; Mulyantari NK
Int J Crit Illn Inj Sci; 2022; 12(4):235-238. PubMed ID: 36779212
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
37. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Dixon B; Smith RJ; Campbell DJ; Moran JL; Doig GS; Rechnitzer T; MacIsaac CM; Simpson N; van Haren FMP; Ghosh AN; Gupta S; Broadfield EJC; Crozier TME; French C; Santamaria JD;
Lancet Respir Med; 2021 Apr; 9(4):360-372. PubMed ID: 33493448
[TBL] [Abstract][Full Text] [Related]
38. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial.
Sanchez O; Charles-Nelson A; Ageno W; Barco S; Binder H; Chatellier G; Duerschmied D; Empen K; Ferreira M; Girard P; Huisman MV; Jiménez D; Katsahian S; Kozak M; Lankeit M; Meneveau N; Pruszczyk P; Petris A; Righini M; Rosenkranz S; Schellong S; Stefanovic B; Verhamme P; de Wit K; Vicaut E; Zirlik A; Konstantinides SV; Meyer G;
Thromb Haemost; 2022 May; 122(5):857-866. PubMed ID: 34560806
[TBL] [Abstract][Full Text] [Related]
39. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
40. Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial With Observational Controls.
Abdelaal Ahmed Mahmoud A; Mahmoud HE; Mahran MA; Khaled M
J Cardiothorac Vasc Anesth; 2020 Feb; 34(2):436-443. PubMed ID: 31262641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
